NCT03842761View on ClinicalTrials.gov

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 6, 2019

Primary Completion Date

April 9, 2021

Study Completion Date

May 20, 2021

Conditions
HealthyHepatic Insufficiency
Interventions
DRUG

BI 685509

Tablet

DRUG

Placebo

Tablet

Trial Locations (1)

78215

American Research Corporation at the Texas Liver Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03842761 - A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems | Biotech Hunter | Biotech Hunter